ANALYST-UPGRADE filed Aug 27, 2026 at 08:16 ET
HC Wainwright & Co. initiated coverage on Ascendis Pharma A/S (ASND) at Buy with a price target of $345, implying 31% upside from the current $263.04. The firm has a 43% accuracy rate on 4,591 calls and an average return of 2.4%, placing it below average among covering firms. Consensus is overwhelmingly bullish, 25 of 26 analysts rate the stock Buy, with only one Hold and no Sell. The mean target is $315.17, median $313.81, high $362.26, and low $270.72. HC Wainwright's $345 target sits above both the mean and median, reflecting an above-consensus view. Momentum is constructive with 2 upgrades and 0 downgrades in the past 30 days, though EPS estimates for the current quarter and year have been revised downward over the past week and month. Insider activity is noteworthy, the Chief Business Officer bought $492,654 worth of shares on August 14, a bullish signal that aligns with the initiation. However, several institutions exited positions completely and short interest sits at a high 68.8% of float, creating a potential squeeze but also elevated risk. The bottom line: a historically below-average firm initiating at Buy with an above-consensus target is moderately bullish but not a game-changer on its own.